CARB-X Partnership Announces Up To $48M Investment In Research To Find New Antibiotics

Washington Post: Quest for new antibiotics gets first major funding from global partnership
“A major global partnership aimed at fighting superbugs announced Thursday that it is investing up to $48 million in research projects, including potentially the first new classes of antibiotics in decades, to target the deadliest drug-resistant bacteria. The investments announced by CARB-X include $24 million in immediate funding for 11 companies. The firms can receive up to $24 million in additional payments over three years if they meet specific milestones. … Funding comes from the Biomedical Advanced Research and Development Authority, or BARDA, part of the Department of Health and Human Services, and the Wellcome Trust, a London-based global biomedical research charity…” (Sun, 3/30).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.